STAAR Surgical stock soars after Alcon raises acquisition offer

Here’s a summary of the most significant insider transactions disclosed on Monday, December 8, 2025.

TOP BUYS

Adverum Biotechnologies (NASDAQ:ADVM) CEO, President and Director Laurent Fischer made a substantial investment in the company, purchasing a total of 128,699 shares worth $553,916. The transactions occurred in two parts: 11,085 shares at an average price of $4.24 on December 5, and 117,614 shares at an average price of $4.31 on December 8. Following these purchases, Fischer now directly owns 201,513 shares, including 1,200 shares acquired through the company’s Employee Stock Purchase Plan.

Adverum Biotechnologies (NASDAQ:ADVM) Chief Operating Officer Peter Soparkar also demonstrated confidence in the company by purchasing 50,000 shares on December 5, 2025. The shares were acquired at a weighted-average price of $4.22, with prices ranging from $4.18 to $4.24, for a total transaction value of $211,000. Following this purchase, Soparkar now directly owns 80,189 shares. This insider buying comes as Adverum’s stock has shown strong performance, up 46.8% over the past six months despite weak financial health indicators.

Annovis Bio, Inc. (NASDAQ:ANVS) Director Michael B Hoffman reported purchasing a total of 45,000 shares worth $193,794 on December 8, 2025. The director acquired 30,000 shares at $4.3398 per share ($130,194) and 15,000 shares at $4.24 per share ($63,600). Following these transactions, Hoffman directly owns 2,574,739 shares of the company. The insider buying comes as ANVS shares have shown strong momentum with a 40.5% price return over the past six months.

LINDE PLC (NYSE:LIN) Chief Executive Officer Lamba Sanjiv acquired 2,520 shares on December 8, 2025, at a weighted average price of $396.68, with prices ranging from $396.39 to $397.00. The total transaction value was $999,633, slightly above the current trading price of $390.09. Following the transaction, Lamba directly owns 90,794.191 shares. This purchase comes at a time when Linde shows good overall financial health with particularly strong profit metrics.

Texas Pacific Land Corp (NYSE:TPL) ten percent owner Horizon Kinetics Asset Management LLC purchased 1 share at $921.79 on December 5, 2025. Following this transaction, Horizon Kinetics directly owns 1,162,580 shares of TPL. The company boasts impressive gross profit margins of 94.13% and has maintained dividend payments for 12 consecutive years.

TOP SELLS

Diamondback Energy, Inc. (NASDAQ:FANG) Director Charles Alvin Meloy sold 377,911 shares at $138.61 per share on December 4, 2025, for a total value of $52,382,243. In addition, Meloy transferred 124,835 shares indirectly via Wolfrock Energy, LLC to trusts for the benefit of his children at no cost.

W.W. Grainger, Inc. (NYSE:GWW) Chairman and CEO Donald G. Macpherson sold 26,302 shares on December 4 and 5, 2025, for approximately $25.9 million. The sales occurred at prices ranging from $962.93 to $978.41 under a Rule 10b5-1 trading plan adopted on September 4, 2025. These transactions come as GWW trades near its 52-week low, down 18.35% over the past year.

Snowflake Inc. (NASDAQ:SNOW) Director Michael L. Speiser sold 50,346 shares on December 5, 2025, at weighted average prices ranging from $230.13 to $233.07, generating total proceeds of approximately $11.7 million. The transactions involved sales of shares held both directly and indirectly through various trusts and a limited partnership. This selling activity comes as SNOW shares have declined 9.21% over the past week.

Eos Energy Enterprises (NASDAQ:EOSE) Director Russell Monoki Stidolph recently sold shares in two separate transactions totaling approximately $11.4 million. On December 5, 2025, Stidolph sold 500,000 shares at $14.99 per share, followed by 30,767 shares on December 8, 2025, at prices ranging from $14.80 to $15.45.

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Chief Medical Officer Jared Gollob sold 49,807 shares on December 8, 2025, for a total of $4,371,832. The sales were executed at prices ranging from $87.37 to $92.19. On the same day, Gollob also exercised options to acquire 49,307 shares at $5.33 per share. The transactions come as Kymera’s stock has shown remarkable momentum, with a 41% return over the last week and a 98% surge over the past six months.

Why Monitor Insider Activity

Tracking insider transactions provides valuable insights into how a company’s executives and directors view their own stock’s prospects. Significant insider buying often signals confidence in the company’s future performance, while substantial selling might raise questions about future growth or valuation concerns. However, investors should remember that insiders sell for many reasons unrelated to company outlook, including diversification, tax planning, or personal financial needs. The most reliable signals come from patterns of insider behavior rather than isolated transactions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Citius Oncology Inc (NASDAQ:CTOR) stock plunged 13.8% in premarket trading Tuesday after the company announced a capital raise of approximately $18 million through registered direct and private placement offerings.

The oncology-focused firm has entered into agreements with a single healthcare-focused investor to sell shares and warrants priced at $1.09 per share, representing an at-the-market offering under Nasdaq rules. The transaction includes the sale of 1,284,404 shares in a registered direct offering and 15,229,358 shares (or pre-funded warrants) in a concurrent private placement.

Both offerings include accompanying warrants that will be exercisable following stockholder approval and will expire five years from the approval date. H.C. Wainwright & Co. is serving as the exclusive placement agent for the transactions, which are expected to close around December 10, 2025.

Citius Oncology plans to use the proceeds to strengthen its cash position and support the commercial launch of LYMPHIR™, its novel cancer immunotherapy developed for cutaneous T-cell lymphoma (CTCL). The funds will also be allocated toward working capital and general corporate purposes.

The stock decline reflects typical market reaction to equity offerings that can potentially dilute existing shareholders’ stakes, despite the capital being raised to fund the company’s growth initiatives.

Citius Oncology is a subsidiary of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) and focuses on developing and commercializing oncology treatments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- SLM Corp. (NASDAQ:SLM) stock is down 14% in premarket trading on Tuesday after the education funding firm’s 2025 investor day forum revealed slower earnings growth projections and higher expenses.

The company hosted its investor forum after Monday’s market close, prompting multiple analyst downgrades. Morgan Stanley downgraded SLM from Overweight to Equalweight and lowered its price target to $31.00 from $36.00, while Compass Point took a more bearish stance, downgrading the stock from Buy to Sell with a price target of $23.00.

Analysts were particularly concerned about the magnitude of potential expense increases as SLM prepares for government pullback and the Graduate PLUS loan opportunity. The company’s illustrative earnings scenario implies a 16% year-over-year expense growth in what analysts consider to be 2026, significantly higher than expected.

The updated outlook represents a major reset that effectively erases about two years of progress. According to Compass Point, current consensus estimates for FY26/FY27 EPS are $3.40/$3.88, but SLM’s updated outlook suggests figures of $2.63/$2.87, approximately 23-26% below consensus expectations.

The company’s FY26 EPS is now projected to decline approximately 19% YoY from the current FY25 outlook midpoint of $3.25. Based on the updated projections, it will take until fiscal 2028 for earnings to return to growth relative to FY25 levels.

While SLM’s investments to capture the Graduate PLUS opportunity and build a more diversified funding structure may create long-term value, the significant near-term earnings reset and execution risks have prompted the negative market reaction.

Investing.com -- Wells Fargo plans to reduce its workforce in 2026 and is preparing for increased severance costs in the fourth quarter of 2025, CEO Charlie Scharf announced on Tuesday.

Scharf shared these plans during his presentation at the Goldman Sachs Financial Services conference, where he outlined the bank’s workforce strategy for the coming year.

The banking executive did not provide specific details about how many positions might be eliminated or which departments would be affected by the planned headcount reduction.

Wells Fargo is also anticipating higher severance-related expenses in the final quarter of this year as it prepares for the workforce changes, though exact figures for these costs were not disclosed during the conference.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.